WHO approves Emergency Use Listing status for Covaxin https://ift.tt/eA8V8J

Bharat Biotech had submitted application for Emergency Use Listing back on April 19, providing all necessary information including the results of the Phase 3 clinical trials in which it demonstrated 77.8 per cent efficacy and further provided 65.2% protection against the new Delta variant.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/3bzFUrC